Skip to main content

Novel Rx

lupus SLE
Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). However, outcomes of therapies within the same class (i.e. BAFF-…
RT @synovialjoints: Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid

Dr. Antoni Chan synovialjoints

3 weeks 1 day ago
Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw
RT @DrPetryna: #abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: i

Olga Petryna DrPetryna

3 weeks 1 day ago
#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE
RT @ericdeinmd: L05 #ACR22 High-dose Denosumab in Erosive Hand OA
48Wk, Double-blind PBO Phase 2 100 patients
GUSS chang

Eric Dein ericdeinmd

3 weeks 1 day ago
L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS change higher in DEN v PBO at w24, incr at w48 New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001) Open label extension w improvement to baseline @RheumNow https://t.co/X6MF9q2bKj
RT @RichardPAConway: Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, R

Richard Conway RichardPAConway

3 weeks 1 day ago
Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW
RT @RichardPAConway: Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher admin

Richard Conway RichardPAConway

3 weeks 1 day ago
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz
RT @uptoTate: In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effect

Dr. Rachel Tate uptoTate

3 weeks 2 days ago
In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO
×